Citigroup and Bank of America issued rating updates for Acadia Pharmaceuticals, alongside insider news regarding James Kihara.
9 reports, 1 independent
Updated Aug 25
Gone quiet
- Reports
- 9
- Developments
- 1
- Repetition
- 89%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Citigroup and Bank of America issued rating updates for Acadia Pharmaceuticals, alongside insider news regarding James Kihara.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Acadia Pharmaceuticals
Pharmaceutical company, which developed Nuplazid, based in San Diego, California.
Nothing else this week.
-
Citigroup
American investment bank and financial services corporation
-
Bank of America
American multinational banking and financial services corporation
Related events
- Bank of America and Citigroup issued buy ratings and boosted price targets for KLA Corporation stock.
- Analyst rating changes for Salesforce, including buy rating upgrades and coverage initiation, were reported on July 18, 2026.
- Citigroup upgraded the stock of Energias de Portugal to 'strong-buy', citing consensus ratings aggregated by MarketBeat. The company is headquartered in Portugal.
- MarketBeat reported consensus ratings, Geode Capital Management raised its stake, Citigroup reissued a buy rating, and Benchmark restated a speculative buy rating regarding Intensity Therapeutics.
- Citigroup restated a buy rating on Currys, while Royal Bank of Canada upgraded shares, with MarketBeat reporting the consensus rating.